Document is current
Any future updates will be listed below
-
Authors
Best, Christoph https://orcid.org/0000-0001-7195-4272
Sayegh, Ana Luiza C.
Janzen, Annette
Oertel, Wolfgang H.
Krämer, Heidrun H.
-
Funding
Funding for this research was provided by:
Justus-Liebig-Universität Gießen
- License Information
-
More Information
Article History
Received: 2 May 2025
Revised: 10 July 2025
Accepted: 17 July 2025
First Online: 30 July 2025
Declarations
:
: C.B.: received lecturing honoraria and consulting fees from Novartis, Bayer and Portola, unrelated to this publication. A.L.S.: there are no conflicts of interest. A.J.: received grants from Parkinson Fonds Deutschland, unrelated to this publication. W.H.O.: received lecturing honoraria from Abbvie, Stada Pharma and the International Movement Disordert Society and consulting fees from Intrabio, Lario Therapeutics and MODAG—all unrelated to this publication. H.H.K.: received travel grants from Alexion and Grifols, lecturing honoraria and consulting fees from Sanofi, Alexion, Roche Pharma, Argenx, UCB and Amgen and research support from Roche and Argenx, unrelated to this publication.
: Before inclusion into the study all participants had given their written informed consent. The study was approved by the local ethics committee of the Medical Faculty of the Justus-Liebig-University, Giessen, Germany (161/11) and performed in accordance with the standards of the Declaration of Helsinki.
